MATTHEW TAYLOR: Open Payments
NPI 1831722271 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,756 in 98 payments from 17 companies in 2025. Trend: 2023 $2,724 · 2024 $2,519 · 2025 $1,756
Food & beverage: $1,743Education: $14
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $622 |
| Janssen Biotech, Inc. | 14 | $242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $137 |
| Madrigal Pharmaceuticals | 6 | $106 |
| Phathom Pharmaceuticals, Inc. | 9 | $100 |
| Ipsen Biopharmaceuticals, Inc | 4 | $89 |
| Aimmune Therapeutics, Inc. | 4 | $74 |
| Gilead Sciences, Inc. | 3 | $67 |
| Intercept Pharmaceuticals, Inc. | 4 | $63 |
| GENZYME CORPORATION | 2 | $47 |
Products named: RINVOQ, TREMFYA, SKYRIZI, REZDIFFRA, VOQUEZNA, LINZESS, DUPIXENT, IQIRVO.
Industry payments across AR — which companies pay providers there.
